NCT00942331 2023-10-16
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
Clinical Trials
7 trialsNCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00110214 2014-05-09
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 3 Completed
NCT00348998 2013-11-06
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00016107 2013-06-05
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027599 2013-02-11
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed